For this phase 3/4 cluster-randomised , double-blind trial , undertaken between Feb 18 , 2009 , and Dec 31 , 2011 , in municipal health-care centres and the Tampere University Vaccine Research Centre ( Finland ) , we randomly assigned ( 2:2:1:1 ) 78 clusters into PHiD-CV10 three plus one , PHiD-CV10 two plus one , control three plus one , control two plus one groups ( 26:26:13:13 clusters ) to give PHiD-CV10 in either three plus one or two plus one schedule ( if enrolled before 7 months of age ; infant schedules ) , two plus one ( if enrolled between 7 and 11 months ; catch-up schedules ) , and two doses at least 6 months apart ( if enrolled between 12 and 18 months ; catch-up schedules ) .